Esperion Therapeutics, Inc. (ESPR) Forms $77.53 Double Top; Fidus Investment (FDUS) SI Decreased By 1.61%

Fidus Investment Corporation (NASDAQ:FDUS) had a decrease of 1.61% in short interest. FDUS’s SI was 30,600 shares in March as released by FINRA. Its down 1.61% from 31,100 shares previously. With 106,600 avg volume, 0 days are for Fidus Investment Corporation (NASDAQ:FDUS)’s short sellers to cover FDUS’s short positions. The stock decreased 0.38% or $0.05 during the last trading session, reaching $12.99. About 151,743 shares traded or 8.38% up from the average. Fidus Investment Corporation (NASDAQ:FDUS) has risen 12.11% since March 16, 2017 and is uptrending. It has underperformed by 4.59% the S&P500.

Esperion Therapeutics, Inc. (ESPR) formed double top with $81.41 target or 5.00% above today’s $77.53 share price. Esperion Therapeutics, Inc. (ESPR) has $2.05B valuation. The stock decreased 2.07% or $1.64 during the last trading session, reaching $77.53. About 503,235 shares traded. Esperion Therapeutics, Inc. (NASDAQ:ESPR) has risen 133.75% since March 16, 2017 and is uptrending. It has outperformed by 117.05% the S&P500.

Among 6 analysts covering Fidus Investment (NASDAQ:FDUS), 3 have Buy rating, 0 Sell and 3 Hold. Therefore 50% are positive. Fidus Investment had 10 analyst reports since January 15, 2016 according to SRatingsIntel. The rating was downgraded by Robert W. Baird on Monday, January 9 to “Neutral”. The firm earned “Mkt Perform” rating on Tuesday, January 10 by Keefe Bruyette & Woods. Oppenheimer maintained the stock with “Buy” rating in Friday, August 4 report. The rating was maintained by Keefe Bruyette & Woods with “Hold” on Wednesday, May 31. The firm has “Hold” rating given on Friday, November 3 by Robert W. Baird. Keefe Bruyette & Woods maintained it with “Hold” rating and $18.0 target in Sunday, October 22 report. Janney Capital initiated Fidus Investment Corporation (NASDAQ:FDUS) on Friday, January 15 with “Neutral” rating. The firm has “Buy” rating by Ladenburg given on Friday, February 16. The company was initiated on Friday, September 23 by DA Davidson. Keefe Bruyette & Woods maintained it with “Hold” rating and $1800 target in Sunday, July 23 report.

Investors sentiment decreased to 1.12 in 2017 Q3. Its down 0.28, from 1.4 in 2017Q2. It dived, as 7 investors sold Fidus Investment Corporation shares while 13 reduced holdings. 10 funds opened positions while 18 raised stakes. 7.12 million shares or 4.90% more from 6.78 million shares in 2017Q2 were reported. Brown Brothers Harriman & accumulated 11,828 shares or 0% of the stock. Raymond James Service Advsrs reported 0.05% stake. Wells Fargo Company Mn, California-based fund reported 3,075 shares. Advsrs Asset Inc invested in 425,517 shares or 0.11% of the stock. Manufacturers Life Ins Communication The has 588 shares. Baystate Wealth Mngmt Ltd Co holds 1,500 shares. Commonwealth Equity Inc holds 11,798 shares. Muzinich And Com invested in 1.25M shares or 1.99% of the stock. Mckinley Capital Mgmt Ltd Com Delaware reported 86,993 shares. Guggenheim Capital Limited Liability Co stated it has 0% of its portfolio in Fidus Investment Corporation (NASDAQ:FDUS). Susquehanna Interest Llp reported 20,742 shares. Cibc Ww holds 10,245 shares. Citigroup invested 0% of its portfolio in Fidus Investment Corporation (NASDAQ:FDUS). Van Eck Associate Corporation reported 174,977 shares. Panagora Asset Mngmt Inc invested in 1,380 shares.

Since March 7, 2018, it had 1 insider purchase, and 0 selling transactions for $91,700 activity. On Wednesday, March 7 Sherard Shelby E bought $91,700 worth of Fidus Investment Corporation (NASDAQ:FDUS) or 7,000 shares.

Analysts await Esperion Therapeutics, Inc. (NASDAQ:ESPR) to report earnings on May, 3. They expect $-1.45 EPS, up 19.44% or $0.35 from last year’s $-1.8 per share. After $-1.44 actual EPS reported by Esperion Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 0.69% negative EPS growth.